Indications

Nausea and vomiting

Contraindication

Prolactin-releasing pituitary tumour, QT prolongation, electrolyte disturbance, cardiac disease (e.g. CHF), GI haemorrhage, mechanical obstruction or perforation. Moderate to severe hepatic impairment. Concomitant use w/ QT-prolonging drugs and potent CYP3A4 inhibitors.

Special Precautions

Hepatic and renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor renal function and ECG regularly, particularly during long-term treatment or in patients w/ predisposing factors for QT prolongation.

Side Effects

Dry mouth; increased prolactin levels (dose dependent) which may lead to galactorrhoea, amenorrhoea, gynaecomastia; breast pain and tenderness; convulsions, dystonic reactions; urticaria, rash, pruritus; transient intestinal cramps, diarrhoea; nervousness, anxiety, decreased libido, asthenia, headache, agitation; oculogyric crisis, urinary retention. Rhythm and heart rate disorders; increased QT interval, atrial fibrillation, arrhythmia, palpitation, ventricular tachycardia, bradycardia; abnormal LFT.

Drug Interactions

May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.

Route of Administration

Oral

Dosage

As directed by the physician